Kathy D. Miller, MD: Hi. I'm Kathy Miller, professor of medicine and co-director of the Simon Cancer Center Breast Cancer Program at the Indiana University School of Medicine in Indianapolis.
Welcome to Medscape Oncology Insights and the 2015 San Antonio Breast Cancer Symposium. The meeting is just underway. As has been the case in the last couple of years, HER2-positive disease is a major focus of our discussions and a major focus of the work at this meeting.
Joining me to put these studies into perspective is Dr Sara Tolaney, senior physician and associate director of clinical research in the Susan Smith Center at the Dana-Farber Cancer Institute in Boston. Welcome, Sara.
Sara Tolaney, MD, MPH: Thank you.
10-Year Results: Still No Definitive Answer on Anthracyclines
Dr Miller: One of the areas of controversy for the last 10 years is whether anthracyclines have a role in the treatment of patients with HER2-positive disease. That controversy was first brought to the forefront by the first results of the BCIRG 006 study,[1] which used a non-anthracycline-containing regimen compared with an anthracycline-trastuzumab regimen. We have the 10-year results at this meeting.[2] Do those 10-year results resolve the controversy?
Dr Tolaney:I think, unfortunately, they do not.
COMMENTARY
Jury Still Out on Anthracyclines in HER2+ Breast Cancer
Kathy D. Miller, MD; Sara Tolaney, MD, MPH
DisclosuresDecember 15, 2015
Kathy D. Miller, MD: Hi. I'm Kathy Miller, professor of medicine and co-director of the Simon Cancer Center Breast Cancer Program at the Indiana University School of Medicine in Indianapolis.
Welcome to Medscape Oncology Insights and the 2015 San Antonio Breast Cancer Symposium. The meeting is just underway. As has been the case in the last couple of years, HER2-positive disease is a major focus of our discussions and a major focus of the work at this meeting.
Joining me to put these studies into perspective is Dr Sara Tolaney, senior physician and associate director of clinical research in the Susan Smith Center at the Dana-Farber Cancer Institute in Boston. Welcome, Sara.
Sara Tolaney, MD, MPH: Thank you.
10-Year Results: Still No Definitive Answer on Anthracyclines
Dr Miller: One of the areas of controversy for the last 10 years is whether anthracyclines have a role in the treatment of patients with HER2-positive disease. That controversy was first brought to the forefront by the first results of the BCIRG 006 study,[1] which used a non-anthracycline-containing regimen compared with an anthracycline-trastuzumab regimen. We have the 10-year results at this meeting.[2] Do those 10-year results resolve the controversy?
Dr Tolaney:I think, unfortunately, they do not.
Medscape Oncology © 2015 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kathy D. Miller, Sara Tolaney. Jury Still Out on Anthracyclines in HER2+ Breast Cancer - Medscape - Dec 15, 2015.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author(s)
Kathy D. Miller, MD
Professor, Indiana University; Codirector, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana
Disclosure: Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Clovis; Nektar; Tessaro; ImClone Systems Incorporated
Received a research grant from: Research grants to Indiana University; salary not contingent on study results. Sponsors include Syndax; Genentech/Roche; Merrimack; Taiho; Macrogenics; Seattle Genetics; Medivation, Inc.
Sara Tolaney, MD, MPH
Instructor, Department of Medicine, Harvard Medical School; Senior Physician, Dana Farber Cancer Institute, Boston, Massachusetts
Disclosure: Sara M. Tolaney, MD, MPH, has disclosed the following relevant financial relationships:
Received research grant from: Genentech